MDMA Exemptions and Special-Use Devices

1. Key takeaways

MDS-G011 (V2.0 / 2025-07-07) states the use-based exemption plainly: devices used for clinical trials, research, education, demonstration, training, custom purposes or national emergency use are exempt from the MDMA (see MDS-REQ 5). The key word is use — the same product imported as a demonstration sample need not hold an MDMA, yet the moment it enters the sales channel it must have one; the two states do not exempt each other merely because the product has not changed. Another gate that is often missed is the import step: importing semi-finished medical devices for production purposes still requires an import licence under MDS-REQ 5, and the MDMA exemption cannot replace that procedure. Clinical-trial use must additionally connect to MDS-REQ 2 (V4.1 / 2022-12-26), because what is exempted is the product’s marketing authorisation, not the clinical research requirements that must still be observed. Regulatory information verified as of 29 October 2026.

• Seven exempted uses: clinical trials, research, education, demonstration, training, custom purposes, national emergency use.
• The exemption attaches to the use of each shipment, not to the product model.
• Semi-finished imports for production still need an MDS-REQ 5 import licence — a separate gate.
• Clinical-trial use additionally follows MDS-REQ 2 (V4.1 / 2022-12-26).

2. Legal basis

The following instruments define the exempted uses, the import and clearance requirements that run in parallel, and the statutory definitions of circulation on which the exemption boundary rests. Third-party retellings are marked as practical estimates with their verification actions.

3. Expert insights

1. The exemption attaches to the use, not the product

This is the sentence most likely to cause trouble. Manufacturers are used to managing compliance status at the SKU level — this model has a certificate, that model does not. The Saudi exemption logic, however, does not sit at the product dimension but at the purpose of each specific flow. Two units of the same model: one enters the country with a trade delegation for demonstration, the other is delivered to a hospital for paid use — the former is exempt, the latter must have an MDMA. If the demonstration unit is sold on the spot to a customer after the exhibition, it drops from exempt to non-compliant, and that shift happens on one internal instruction, invisible from the outside. The management action must therefore change from labelling models to labelling every shipment, with the declared use, the port of entry and the final destination of each batch recorded in the ERP or the ledger.

2. Why the Law counts free provision as circulation

To understand the exemption boundary, first understand the default state. Law M/54 Article 1 defines Circulation as the provision of devices or supplies, for consideration or free of charge, whether for distribution or use, and the Marketing Authorization as the document permitting a device to circulate. In other words, the law’s default control point is whether the item is being provided to others, not whether money changed hands. The rationale is direct: the risk to patients does not differ because the device was bought, gifted, lent or demonstrated — a device without an MDMA used on a patient carries exactly the same risk. Exemption clauses therefore have to be written as an explicit list of exceptions rather than a blanket no-sale-no-rules rule. Donations, public-interest deployment and academic support devices must be checked against the exempted-use list before arrangement; otherwise their nature is circulation.

3. The import licence is another independent gate

Holding an MDMA does not mean customs clearance is possible, and lacking one does not mean clearance procedures are unnecessary — these are 2 independent gates. Importing semi-finished products for production purposes requires an import licence under MDS-REQ 5, a line that runs in parallel with any MDMA exemption. The common practical misunderstanding is the assumption that this batch is MDMA-exempt research products so it can simply be shipped, which then stalls at the port: the exemption resolves the marketing authorisation, while the clearance step has its own release logic and application procedures. Furthermore, where the use is a clinical trial, the clinical research requirements of MDS-REQ 2 (V4.1 / 2022-12-26) must also be observed — the exemption lifts the marketing authorisation duty, not the research and ethics requirements. Another point worth noting: the import step is also tied to establishment qualifications and the importer’s MDEL activity scope; when a third party handles the import, first check whether its licence scope covers such goods. The complete logic of import clearance is in https://www.grzan.cn/regulations/saudi/import-clearance-and-shipment-permit-36 ; the MDEL activity scope requirements are in https://www.grzan.cn/regulations/saudi/medical-device-establishment-licence-34 .

4. Practical recommendations

• Attach a use label to every shipment: clinical trial, research, education, demonstration, training, custom, national emergency use, regular sale — one of eight, no blanks.
• Build a return-or-scrap closed loop for demonstration and training units, avoiding post-exhibition conversion into sales that bypasses the MDMA requirement.
• Open a separate MDS-REQ 2 compliance file for clinical-trial use; do not treat the exemption as a get-out clause.
• Custom devices must additionally be measured against MDS-G030 Scope Exclusions item 3 — judge the two rules separately; neither substitutes for the other.
• Companies importing semi-finished products for production should schedule the MDS-REQ 5 import licence application into the production plan and allow ample processing time.
• Where a third party handles import, verify whether the other party’s MDEL activity scope covers the goods in question.
• Keep the order and fitting records proving the custom device–patient correspondence, so inspections can confirm the custom character. GRZAN additionally recommends keeping a written statement that the device will not enter regular sales channels, to prevent the boundary being broken.

5. Verification checklist

• □ Every shipment to be exported or cleared has its declared use labelled
• □ That use genuinely falls within the exemption list: clinical trial, research, education, demonstration, training, custom purposes, national emergency use
• □ Clinical-trial uses have the complete supporting materials per MDS-REQ 2 (V4.1)
• □ A written return, re-export or scrap closed loop exists for demonstration and training units
• □ Where semi-finished products are imported for production, the MDS-REQ 5 import licence has been obtained
• □ The importer’s MDEL activity scope covers the device categories imported this time
• □ Custom devices have order and fitting records retained, plus a written statement of no regular sale
• □ The internal ledger has moved from model-based management to batch-plus-use management

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Saudi Arabian market. Our team manages SFDA MDMA applications across classes, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzan.com